Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Enzyte lawsuit

This article was originally published in The Tan Sheet

Executive Summary

Male enhancement supplement manufacturer Berkeley Premium Nutraceuticals made unsubstantiated claims about Enzyte's ability to increase penis size "despite [Berkeley's] knowledge that there was no legitimate scientific basis supporting the claims," alleges a class-action lawsuit filed in Montgomery, Ohio County Court, March 17. The suit is filed on behalf of a consumer who paid $400 for an eight-month supply of the product and received only a portion of the refund he was promised after the product did not work as promised. Firm recently was asked by the Council of Better Business Bureau's National Advertising Division to discontinue performance claims because anecdotal evidence supporting the claims was found to be insufficient (1"The Tan Sheet" Aug. 25, 2003, p. 16)...

You may also be interested in...

Enzyte Marketers’ Prison Time Could Scare Firms Off Fraudulent Claims

In a decision that will make executives think twice before taking part in making false claims and other deceptive behavior, an Ohio court sentenced 11 former employees of Berkeley Premium Nutraceuticals to prison for conspiracy, fraud and money laundering convictions related to marketing its Enzyte "natural male enhancement" product

Enzyte Male Enhancement Program Claims Overly Enhanced

Lifekey Healthcare should discontinue performance and efficacy claims for its Enzyte Male Enhancement Program, due in part to insufficient clinical evidence of the product's performance and efficacy, the National Advertising Division says

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts